Literature DB >> 24553597

Plasma exchange and immunosuppressive therapy in a case of mild haemophilia A with inhibitors and a life-threatening lower limb haemorrhage.

Chiara Ambaglio1, Fabio Lodo1, Alice Trinchero1, Nicola Ghidelli1, Cesare Perotti2, Claudia Del Fante2, Gabriella Gamba1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24553597      PMCID： PMC3926713          DOI： 10.2450/2014.0160-13

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  27 in total

Review 1.  Treatment of patients with factor VIII and IX inhibitors.

Authors:  I M Nilsson; E Berntorp; C Freiburghaus
Journal:  Thromb Haemost       Date:  1993-07-01       Impact factor: 5.249

2.  Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb).

Authors:  M Jansen; S Schmaldienst; S Banyai; P Quehenberger; I Pabinger; K Derfler; W H Hörl; P Knöbl
Journal:  Br J Haematol       Date:  2001-01       Impact factor: 6.998

3.  Long term outcome of patients with acquired haemophilia--a monocentre interim analysis of 82 patients.

Authors:  H Zeitler; G Goldmann; N Marquardt; G Ulrich-Merzenich
Journal:  Atheroscler Suppl       Date:  2013-01       Impact factor: 3.235

4.  Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee.

Authors:  G Mariani; A Ghirardini; R Bellocco
Journal:  Thromb Haemost       Date:  1994-07       Impact factor: 5.249

Review 5.  Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

Authors:  A Sharathkumar; D Lillicrap; V S Blanchette; M Kern; J Leggo; A M Stain; L Brooker; M D Carcao
Journal:  J Thromb Haemost       Date:  2003-06       Impact factor: 5.824

6.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.

Authors:  S Ehrenforth; W Kreuz; I Scharrer; R Linde; M Funk; T Güngör; B Krackhardt; B Kornhuber
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

7.  Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb).

Authors:  P Knöbl; K Derfler; L Korninger; S Kapiotis; U Jäger; T Maier-Dobersberger; W Hörl; K Lechner; I Pabinger
Journal:  Thromb Haemost       Date:  1995-10       Impact factor: 5.249

8.  Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group.

Authors:  Y Sultan
Journal:  Thromb Haemost       Date:  1992-06-01       Impact factor: 5.249

9.  Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

Authors:  I M Nilsson; E Berntorp; O Zettervall
Journal:  N Engl J Med       Date:  1988-04-14       Impact factor: 91.245

10.  Low-dose immune tolerance induction in hemophilia A patients with inhibitors.

Authors:  E P Mauser-Bunschoten; H K Nieuwenhuis; G Roosendaal; H M van den Berg
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.